---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-032952"
form_type: "8-K"
ticker: "ARDX"
cik: "0001437402"
company_name: "ARDELYX, INC."
filed_at: "2023-09-25T23:59:59+00:00"
generated_at: "2026-06-10T09:11:53.502710+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ardelyx receives $30M milestone payments from Kyowa Kirin on Japan approval of tenapanor

## Summary
- Kyowa Kirin received MHLW approval in Japan for tenapanor for hyperphosphatemia in adult CKD patients on dialysis.
- Approval triggers $30M in milestone and amendment payments from Kyowa Kirin to Ardelyx.
- Ardelyx also receives $5M from HealthCare Royalty Partners under its existing agreement.
- Ardelyx may receive an additional $5M from HealthCare Royalty Partners if net sales in Japan exceed a target by 2025.

## SEC filing metadata
- accession: 0001628280-23-032952
- form_type: 8-K
- ticker: ARDX
- cik: 0001437402
- company_name: ARDELYX, INC.
- filed_at: 2023-09-25T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1437402/000162828023032952/0001628280-23-032952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1437402/000162828023032952/ardx-20230925.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-032952
- JSON: https://secwatch.observer/filing/0001628280-23-032952.json
- Plain text: https://secwatch.observer/filing/0001628280-23-032952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.